Bio-Rad Laboratories, Inc. (BIO) vs Vaxcyte, Inc. (PCVX)

A side-by-side comparison of Bio-Rad Laboratories, Inc. and Vaxcyte, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Bio-Rad Laboratories, Inc. logo
BIO
Bio-Rad Laboratories, Inc.
$10.02B
$372.38HealthcareDelayed quote: Oct 6, 2026, 1:19 PM EDT
Vaxcyte, Inc. logo
PCVX
Vaxcyte, Inc.
$9.40B
$65.11HealthcareDelayed quote: Oct 6, 2026, 1:15 PM EDT

Total return — BIO vs PCVX

growth of $100 · dividends reinvested · last 6y
BIO -17.4% (-3.1%/yr)PCVX +182.3% (+18.9%/yr)PCVX compounded faster over this window
100200300400Start $100202120222023202420252026$83$282
BIO PCVX

BIO vs PCVX: by the numbers

  • •BIO is the larger company ($10.02B vs $9.40B market cap).
  • •BIO is profitable (8.59% net margin) while PCVX runs a net loss (0.00%).

Metrics side by side

Valuation

MetricBIOPCVX
P/E ratio45.14N/A
Forward P/E38.20N/A
P/S ratio3.87N/A
P/B ratio1.403.41
EV / EBITDA28.00N/A
FCF yield3.52%N/A

Profitability

MetricBIOPCVX
Gross margin51.90%0.00%
Operating margin9.08%0.00%
Net margin8.59%0.00%
ROE3.10%-38.59%
ROIC1.54%-40.65%

Growth (annualized)

MetricBIOPCVX
Revenue CAGR (5Y)0.29%N/A
EPS CAGR (5Y)-26.27%N/A
FCF CAGR (5Y)-9.65%N/A
Total return CAGR (5Y)-12.10%25.08%

Frequently asked

Is BIO or PCVX more profitable?
BIO runs the higher net margin — BIO at 8.59% versus PCVX at 0.00%.
How have BIO and PCVX total returns compared?
Over the past 5 years, BIO delivered -12.10% and PCVX delivered 25.08% annualized total return. Past performance doesn't predict future results.

Go deeper

Full BIO analysisFull PCVX analysisInteractive comparison tool

Dig into the metrics

Bio-Rad Laboratories P/E ratioBio-Rad Laboratories ROEVaxcyte ROEBio-Rad Laboratories operating marginVaxcyte operating marginBio-Rad Laboratories revenue growthVaxcyte revenue growthBio-Rad Laboratories free cash flowVaxcyte free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.